- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00094120
MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula.
Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with "wet" AMD.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, United States, 19462
- Genaera Corporation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a diagnosis of "wet" age-related macular degeneration
Exclusion Criteria:
- Prior treatment for "wet" age-related macular degeneration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Protective Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Anticarcinogenic Agents
- Squalamine
Other Study ID Numbers
- MSI-1256F-208
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheNot yet recruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
University of Modena and Reggio EmiliaCompletedMacular Degeneration Advanced | Macular Degeneration, Dry | Macular Degeneration, Senile | Macular Scar | Macular Degeneration NonexudativeItaly
-
Shanghai Refreshgene Technology Co., Ltd.RecruitingNeovascular Age-related Macular DegenerationChina
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
Clinical Trials on MSI-1256F (Squalamine Lactate)
-
Genaera CorporationTerminatedMacular DegenerationUnited States
-
Genaera CorporationTerminatedMacular DegenerationUnited States
-
Starr MuscleOhr Pharmaceutical Inc.WithdrawnDiabetic RetinopathyUnited States
-
Genaera CorporationTerminated"Wet" Age-Related Macular DegenerationUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Unknown
-
Ohr Pharmaceutical Inc.CompletedNeovascular Age Related Macular DegenerationUnited States
-
Elman Retina GroupCompletedRetinal NeovascularizationUnited States
-
Ohr Pharmaceutical Inc.Cumberland Valley Retina Consultants, PCCompletedMacular Edema | Retinal Vein Occlusion
-
Ohr Pharmaceutical Inc.WithdrawnAge-Related Macular DegenerationUnited States
-
Nantes University HospitalCompleted